Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00499291
Other study ID # CDR0000554709
Secondary ID ECOG-E1Y06
Status Withdrawn
Phase N/A
First received
Last updated
Start date September 2006

Study information

Verified date May 2023
Source Eastern Cooperative Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with advanced or refractory solid tumors.


Description:

OBJECTIVES: Primary - To develop a population pharmacokinetic model for paclitaxel administered as paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) to a large population of patients with advanced or refractory cancer to characterize the inter-individual pharmacokinetic variability of this agent. Secondary - To explore nab-paclitaxel pharmacokinetic parameters in patients with metastatic prostate cancer (castrate), metastatic breast cancer, advanced non-small cell lung cancer and other incurable advanced or refractory tumors amenable to treatment with nab-paclitaxel. - To explore the association between exposure to total and unbound paclitaxel after administration of nab-paclitaxel and neutropenia. - To explore the association between the CYP2C8*3 variant and paclitaxel clearance. - To explore the association between other variants of CYP2C8 and other genes involved in paclitaxel disposition including CYP3A4, CYP3A5, SLCO1B3 (OATP8), and ABCB1 (MDR1) and paclitaxel pharmacokinetic parameters and toxicity after one course of treatment. OUTLINE: This is a multicenter study. Patients receive paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) IV over 30 minutes on days 1, 8, 15, 22, 29, 36, 43, and 50. Treatment may repeat off study every 9 weeks in the absence of disease progression or unacceptable toxicity. Serial blood samplings are obtained at specified time points during course 1 including baseline and days 1 and 8 of course 1 for pharmacokinetic studies. Samples are also examined for genotype by PCR including variant genotypes in 2C8, CYP3A4, CYP3A5, ABCB1, ABCC2, ABCC10 and OATP1B3 genes.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS: - Patients must have an incurable advanced or refractory tumor amenable to treatment with paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) - Per the National Comprehensive Cancer Network, the following cancer sites have been shown to be responsive to taxane therapy: - Prostate cancer - Breast cancer - Non-small cell lung cancer - Bladder cancer - Head and neck cancer - Oral cancer - Cervical cancer - Ovarian cancer - Endometrial cancer - Esophageal cancer - Gastric cancer - Germ cell tumors - Tumors of unknown primary - Soft tissue sarcomas - Small cell lung cancer - Testicular cancer - Upper genitourinary tract cancers PATIENT CHARACTERISTICS: - Patients must have performance status 0-2 by the ECOG scale - Absolute neutrophil count = 1,500/µL - Platelet count = 100,000/µL - Hemoglobin = 9 g/dL - Bilirubin = institutional upper limit of normal (ULN) - ALT and AST = 2.5 x ULN - Alkaline phosphatase = 2.5 x ULN (if bone metastasis is present in the absence of liver metastasis, alkaline phosphatase must be = 5 x ULN) - Creatinine = 1.5 x ULN - Patients must not have baseline sensory neuropathy = grade 2 - Women must not be pregnant or breastfeeding - Negative blood or urine pregnancy test - Women of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception PRIOR CONCURRENT THERAPY: - Prior treatment is allowed, which may include prior taxane therapy - If patient has had prior therapy(ies), s/he must have received last treatment = 28 days prior to registration - Patients must not be receiving colony stimulating factors (CSFs) - Previous CSFs must have been discontinued > 14 days prior to registration - Patients must not be receiving concomitant treatment with any of the following (prior use is allowed, but must have been discontinued = 28 days prior to registration): - Phenytoin - Carbamazepine - Barbiturates - Rifampicin - Phenobarbital - Hypericum perforatum (St. John's wort) - Ketoconazole

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
paclitaxel albumin-stabilized nanoparticle formulation

Procedure:
gene expression analysis

laboratory biomarker analysis

pharmacological study

polymerase chain reaction


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Eastern Cooperative Oncology Group National Cancer Institute (NCI)

Outcome

Type Measure Description Time frame Safety issue
Primary Inter-individual pharmacokinetic variability
Secondary Pharmacokinetic parameters
Secondary Neutropenia
Secondary CYP2C8*3 variant expression
Secondary Genetic variance relating to pharmacokinetics and toxicity
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients